GlassScriptPhysician profile
Jack D Hydrick
NPI 1053382648
$9,006.54
in general payments reported to CMS, 2019-2025
38 companies · $2,182 in 2025
The $2,182 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,192 · 2022: $1,885 · 2023: $1,673 · 2024: $2,074 · 2025: $2,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,929.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,415.76 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $808.11 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $781.57 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $770.85 | 2022 | |
| Novo Nordisk INC | $720.00 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $641.54 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $559.04 | 2021-2025 | Zepbound, Mounjaro, Kisunla |
| Axsome Therapeutics, INC. | $476.97 | 2023-2025 | Auvelity, Symbravo |
| Vanda Pharmaceuticals INC. | $381.61 | 2024-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $365.04 | 2022-2025 | Caplyta |
| Antares Pharma, INC. | $347.30 | 2021-2025 | Xyosted |
| Lundbeck LLC | $219.04 | 2023-2025 | Vyepti, Rexulti |
| Astrazeneca Pharmaceuticals LP | $188.15 | 2021-2025 | Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.52 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $145.72 | 2021-2024 | Trintellix |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Hydrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.